Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin

Cancer

Volumn 79, Issue 8, 1997, Pages 1623-1628

  Dunphy, Frank R ^a   Dunleavy, Teresa L ^a   Harrison, Bruce R ^a   Boyd, James H ^a   Varvares, Mark A ^a   Dunphy, Cherie H ^a   Rodriguez, Jack J ^a   McDonough, Erin M ^a   Minster, Jeffrey R ^b   McGrady, Murray D ^c  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c Belleville Otolaryngology Associates   (United States)

Author keywords

anemia; carboplatin; drug induced; erythropoietin; head and neck carcinoma; paclitaxel

Indexed keywords

CARBOPLATIN; ERYTHROPOIETIN; FERRITIN; FERROUS SULFATE; FOLIC ACID; HEMOGLOBIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; IRON BINDING CAPACITY; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEAD AND NECK NEOPLASMS; HEMOGLOBIN A; HUMANS; MIDDLE AGED; PACLITAXEL;

EID: 0030900218     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1623::AID-CNCR28>3.0.CO;2-Z     Document Type: Article

References (20)

1. Weirnik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-93.
2. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:1171-7.
3. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13(8):1860-70.
4. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (TAXOL). Semin Oncol 1993;20(4)(Suppl 3):1-15.
5. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985;12(Suppl A):125-36.
6. Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E. Phase II study of JM8, a new platinum analog in advanced ovarian carcinoma. Cancer Treat Rep 1983;67(11):997-1001.
7. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7(11):1748-56.
8. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83(24):1797-805.
9. Seidman AD, Reichman BS, Crown JP, Yao T-J, Currie V, Hakes TB, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13(5):1152-9.
10. Speilmann M. Taxol (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interim results of a multinational study. Oncology 1994; 51(Suppl 1):25-8.
11. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87(15):1169-75.
12. Seidman AD, Tiersten A, Hudis C, Gollub M, Barren S, Yao T-J, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13(10):2575-81.
13. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12(2):241-8.
14. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-hodgkin's lymphoma. J Clin Oncol 1995;13(3):583-7.
15. Hasegawa I, Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol Oncol 1992;46:65-8.
16. Miller CB, Platanias LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992;84:98-103.
17. Medenica R, Huschart T. Erythropoietin prevents anemia in chemotherapy cancer patients [abstract 608]. Blood 1990; 76:154.
18. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer 1993;67:156-8.
19. Bookman MA, McGuire WP, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14(6):1895-902.
20. Minster JR, Dunleavy TL, Dunphy FR, Boyd JH, Varvares MA, McDonough EM, et al. Erythropoietin (EPO) - A cost effective alternative to transfusions in patients with advanced head and neck cancers undergoing chemotherapy? Proc Am Soc Hematology, Blood 1995;86(10)(Suppl 1):700.